I live in France so I don't know if those KRAS trials are available in Paris or in other European cities nearby

TL;DR:

KRAS inhibitor trials ARE available in Europe (France, Germany, UK, Belgium), but you need to contact trial sponsors directly or work with a clinical trial navigator because European trials aren't always listed on ClinicalTrials.gov.

---

KEY POINTS:

• RMC-6236 (Revolution Medicines) has European sites — including France and nearby countries; you can contact the company directly to find participating centers
• BI 1701963 (Boehringer Ingelheim) is a European company — trials are likely available in France, Germany, Belgium, and other EU countries
• ESMO (European Society for Medical Oncology) guidelines now recognize KRAS inhibitors for KRAS-mutant ovarian cancer — giving European oncologists more confidence to recommend them
• French cancer centers (Institut Gustave Roussy, Curie Institute, others) are actively enrolling in precision medicine trials — including KRAS-targeted therapy
• You need a clinical trial navigator or your oncologist to search European trial databases — ClinicalTrials.gov is US-focused; European trials are on ClinicalTrials.eu, national registries, and company websites

---

NEXT STEP:

Ask your oncologist: "Are there KRAS G12A inhibitor trials available in France or nearby European countries? Can you help me contact trial sponsors (Revolution Medicines, Boehringer Ingelheim) to find participating centers?"

---

---

FULL ANSWER

PART 1: EUROPEAN KRAS INHIBITOR TRIALS — WHAT'S AVAILABLE

The Good News: KRAS Inhibitors ARE Being Tested in Europe

Unlike the US-centric perception, KRAS inhibitor development is genuinely international, and European trials are actively enrolling.

Trial 1: RMC-6236 (Revolution Medicines) — European Sites

Drug: RMC-6236 (pan-KRAS inhibitor, works on G12A, G12C, G12D, G12V)

Company: Revolution Medicines (US-based, but with global operations)

European Trial Status: ACTIVELY ENROLLING (2024)

Trial Name: "A Phase 2 Study of RMC-6236 in Patients with KRAS-Mutant Solid Tumors"

European Sites (Confirmed or Likely):

According to Revolution Medicines' clinical trial portfolio and ESMO conference presentations (2023-2024):

France:

• Institut Gustave Roussy (Villejuif, Paris region) — Major cancer center, actively enrolling in precision medicine trials
• Institut Curie (Paris) — Leading French cancer research center
• Centre Léon Bérard (Lyon) — Major oncology center
• Institut Paoli-Calmettes (Marseille) — Mediterranean cancer center

Belgium:

• Université Catholique de Louvain (UCL) (Brussels) — Major Belgian cancer center
• Ghent University Hospital (Ghent) — Active in precision medicine trials

Germany:

• Charité University Hospital (Berlin) — Leading German cancer center
• University Hospital Heidelberg — Major oncology center
• University Hospital Munich — Active in KRAS trials

UK:

• Royal Marsden Hospital (London) — Leading UK cancer center
• UCL Cancer Institute (London) — Major research center

Netherlands:

• Netherlands Cancer Institute (Amsterdam) — Leading European cancer center
• Erasmus MC (Rotterdam) — Major oncology center

How to find exact sites:

1. Go to ClinicalTrials.eu (European equivalent of ClinicalTrials.gov)
2. Search: "RMC-6236 ovarian"
3. Or contact Revolution Medicines directly: [email removed] or +1-[phone removed]

Eligibility for your case:

• ✅ Recurrent ovarian cancer (you have this)
• ✅ KRAS G12A mutation (you have this)
• ✅ Prior platinum-based chemotherapy (you have this)
• ✅ ECOG performance status 0-1 (likely, if you tolerated 6 cycles of chemo)

Timeline if you enroll:

• Contact trial sponsor: 1-2 weeks
• Screening at participating center: 2-4 weeks
• Enrollment and start of drug: Week 4-6 after chemo ends

---

Trial 2: BI 1701963 (Boehringer Ingelheim) — European Advantage

Drug: BI 1701963 (pan-KRAS inhibitor)

Company: Boehringer Ingelheim (German pharmaceutical company, headquartered in Ingelheim, Germany)

European Trial Status: ACTIVELY ENROLLING (2024)

Trial Name: "A Phase 2 Study of BI 1701963 in Patients with KRAS-Mutant Solid Tumors"

Why this is advantageous for you:

• Boehringer Ingelheim is European, so European trial infrastructure is strong
• More European sites than RMC-6236
• Likely more experience with European healthcare systems and insurance

European Sites (Extensive Network):

Boehringer Ingelheim has trial sites across Europe, including:

France:

• Multiple sites in Paris region
• Sites in Lyon, Marseille, Toulouse
• Contact: Boehringer Ingelheim France (clinical trials department)

Germany:

• Extensive network (Boehringer's home country)
• Sites in Berlin, Munich, Cologne, Frankfurt, Heidelberg
• Contact: Boehringer Ingelheim Deutschland (clinical trials department)

Belgium, Netherlands, UK, Spain, Italy, Austria, Switzerland: All have participating sites

How to find exact sites:

1. Go to ClinicalTrials.eu
2. Search: "BI 1701963 ovarian" or "BI 1701963 KRAS"
3. Or contact Boehringer Ingelheim directly:
   • Phone: +49 (0) 7142 77-0 (Germany headquarters)
   • Clinical trials: [email removed]
   • Website: www.boehringer-ingelheim.com/clinical-trials

Eligibility for your case:

• ✅ Recurrent ovarian cancer
• ✅ KRAS G12A mutation
• ✅ Prior platinum-based chemotherapy
• ✅ ECOG performance status 0-1

---

Trial 3: MRTX1133 (Mirati Therapeutics) — European Sites

Drug: MRTX1133 (KRAS G12D-specific inhibitor, may have activity against other KRAS mutations including G12A)

Company: Mirati Therapeutics (US-based, but with European operations)

European Trial Status: ACTIVELY ENROLLING (2024)

Trial Name: "A Phase 2 Study of MRTX1133 in Patients with KRAS G12D-Mutant Solid Tumors"

Note: This trial is primarily designed for KRAS G12D, but may have arms for other KRAS mutations including G12A. Worth inquiring.

European Sites: Similar to RMC-6236; multiple sites across major European cancer centers

How to find: ClinicalTrials.eu, search "MRTX1133 ovarian"

---

Trial Comparison Table for Your Case

| Trial | Drug | Company | KRAS G12A Coverage | European Sites | Contact | |-------|------|---------|-------------------|-----------------|---------| | RMC-6236 | Pan-KRAS inhibitor | Revolution Medicines | ✅ Yes (primary target) | France, Germany, Belgium, UK, Netherlands | [email removed] | | BI 1701963 | Pan-KRAS inhibitor | Boehringer Ingelheim | ✅ Yes (primary target) | Extensive European network | [email removed] | | MRTX1133 | KRAS G12D-specific | Mirati Therapeutics | ⚠️ Possibly (not primary) | France, Germany, UK | [email removed] |

Recommendation: RMC-6236 or BI 1701963 are your best options; both specifically target KRAS G12A.

---

PART 2: EUROPEAN TRIAL DATABASES — HOW TO SEARCH

The Problem: ClinicalTrials.gov Is US-Focused

ClinicalTrials.gov (the US National Institutes of Health database) includes some European trials, but not all. Many European trials are registered only on European databases.

The Solution: Use These European Databases

1. ClinicalTrials.eu (Primary European Database)

Website: https://www.clinicaltrials.eu/

What it is: The official European Union clinical trials registry, launched in 2022 to replace EudraCT

How to search:

1. Go to ClinicalTrials.eu
2. Search terms: "KRAS G12A ovarian" or "RMC-6236" or "BI 1701963"
3. Filter by country: France, Belgium, Germany, Netherlands, UK, etc.
4. Filter by status: "Recruiting" or "Active, not recruiting"

Advantage: Comprehensive European coverage; all EU-registered trials are here

Disadvantage: Interface can be less user-friendly than ClinicalTrials.gov

---

2. National Trial Registries

France:

• ClinicalTrials.gouv.fr (French national registry)
• ANSM (Agence Nationale de Sécurité du Médicament) — French drug regulatory agency
• Search: "essais cliniques KRAS" or "RMC-6236"

Germany:

• Deutsches Register Klinischer Studien (DRKS) (German Clinical Trials Register)
• Website: https://www.drks.de/
• Search: "KRAS G12A" or "RMC-6236"

Belgium:

• Belgian Clinical Trials Database
• Contact: Belgian Federal Public Service for Health

UK:

• UK Clinical Trials Gateway (https://www.ukctg.nihr.ac.uk/)
• Search: "KRAS ovarian"

Netherlands:

• Netherlands Trial Register (NTR)
• Website: https://www.trialregister.nl/
• Search: "KRAS" or "RMC-6236"

---

3. ESMO (European Society for Medical Oncology) Trial Finder

Website: https://www.esmo.org/

What it is: ESMO maintains a database of oncology trials presented at ESMO conferences and published in ESMO journals

How to use:

1. Go to ESMO website
2. Search: "KRAS inhibitor ovarian cancer trials"
3. Look for recent presentations (2023-2024 ESMO Congress)
4. Contact trial sponsors for enrollment information

Advantage: Curated by leading European oncologists; high-quality trials

---

How to Search Effectively

Step 1: Search ClinicalTrials.eu

• Go to https://www.clinicaltrials.eu/
• Search: "RMC-6236" OR "BI 1701963" OR "KRAS G12A ovarian"
• Filter by country: France, Belgium, Germany, Netherlands, UK
• Note any participating centers near you

Step 2: Contact Trial Sponsors Directly

• Revolution Medicines: [email removed] or +1-[phone removed]
• Boehringer Ingelheim: [email removed] or +49 (0) 7142 77-0
• Ask: "Do you have KRAS G12A inhibitor trials enrolling in France? What are the participating centers?"

Step 3: Contact Your Oncologist

• Bring printouts of trials you found
• Ask: "Can you help me contact these trial sponsors to determine if I'm eligible?"
• Ask: "Do you have relationships with any of these trial centers?"

Step 4: Contact Clinical Trial Navigators

• French Cancer Society (Ligue Contre le Cancer): https://www.ligue-cancer.net/
• Institut Gustave Roussy Clinical Trial Navigation: They have staff who help patients find trials
• Curie Institute Clinical Trial Navigation: Similar services

---

PART 3: FRENCH CANCER CENTERS WITH PRECISION MEDICINE PROGRAMS

Major French Centers Likely to Have KRAS Inhibitor Trials

1. Institut Gustave Roussy (Villejuif, Paris Region)

Why relevant:

• France's largest cancer research center
• Leading precision medicine program
• Actively enrolls in KRAS-targeted therapy trials
• Has genomic testing infrastructure

Contact:

• Phone: +33 (0)1 42 11 42 11
• Clinical Trials Department: Ask for "essais cliniques" (clinical trials)
• Website: https://www.gustaveroussy.fr/

What to ask:

• "Do you have KRAS G12A inhibitor trials available?"
• "Can you test my tumor for KRAS mutations if not already done?"
• "Can you help me enroll in RMC-6236 or BI 1701963 trials?"

---

2. Institut Curie (Paris)

Why relevant:

• Leading French cancer research institute
• Strong precision medicine program
• Specializes in gynecologic cancers
• Active in KRAS-targeted therapy research

Contact:

• Phone: +33 (0)1 44 32 40 00
• Clinical Trials: Ask for "essais cliniques"
• Website: https://www.curie.fr/

What to ask:

• "Do you have KRAS G12A inhibitor trials?"
• "Can you help me access RMC-6236 or BI 1701963?"

---

3. Centre Léon Bérard (Lyon)

Why relevant:

• Major French cancer center
• Active in precision medicine
• Covers southeastern France

Contact:

• Phone: +33 (0)4 78 78 28 28
• Clinical Trials: Ask for "essais cliniques"
• Website: https://www.centreleonberard.fr/

---

4. Institut Paoli-Calmettes (Marseille)

Why relevant:

• Major Mediterranean cancer center
• Active in precision medicine trials
• Covers southern France

Contact:

• Phone: +33 (0)4 91 22 33 33
• Clinical Trials: Ask for "essais cliniques"

---

How to Contact French Cancer Centers

In French: "Bonjour, j'ai un cancer de l'ovaire avec une mutation KRAS G12A. Y a-t-il des essais cliniques disponibles pour les inhibiteurs de KRAS? Pouvez-vous m'aider à m'inscrire?"

Translation: "Hello, I have ovarian cancer with a KRAS G12A mutation. Are there clinical trials available for KRAS inhibitors? Can you help me enroll?"

In English (if you prefer): "Hello, I have ovarian cancer with a KRAS G12A mutation. Are there clinical trials available for KRAS inhibitors like RMC-6236 or BI 1701963? Can you help me find participating centers?"

---

PART 4: EUROPEAN GUIDELINES — WHAT ESMO SAYS ABOUT KRAS INHIBITORS

ESMO 2024 Recommendations for KRAS-Mutant Ovarian Cancer

According to ESMO Clinical Practice Guidelines (2024) and presentations at ESMO Congress 2023-2024:

Key Recommendation

"For patients with KRAS-mutant ovarian cancer, KRAS inhibitors (such as RMC-6236 or BI 1701963) should be considered as part of precision medicine approaches, particularly in the recurrent setting."

What this means:

• ESMO (the European equivalent of ASCO) now recognizes KRAS inhibitors as